

## Sustainability-Related Disclosures:

### VARIOPARTNER SICAV - SECTORAL HEALTHCARE OPPORTUNITIES FUND

#### Summary:

---

This disclosure is made by the VARIOPARTNER SICAV - SECTORAL HEALTHCARE OPPORTUNITIES FUND (the 'Sub-Fund') pursuant to Article 10 of the Sustainable Finance Disclosure Regulation (EU) 2019/2088 ('SFDR').

#### The Sub-Fund:

- Mainly promotes social characteristics by investing partially in sustainable investments with a social objective. These consist of companies that contribute to an investment in human capital (good health and well-being), product quality and safety, tackling inequality by providing access to medicine, social integration and labour relations or independence of the board, and that the Investment Manager has identified as sustainable investments. These companies are innovative healthcare companies developing differentiated drugs, services, life science tools and devices in therapeutic areas with large unmet medical needs.
- Also promotes certain minimum environmental standards and/or business practices. Therefore, it invests in issuers that the Investment Manager considers well-prepared to handle material ESG (Environmental, Social and Governance) matters and by avoiding investments in issuers that are involved in severe controversies (i.e. that have a high controversy score).

The sustainable investments that the Sub-Fund financial product partially intends to make have the social objective of improving good health and well-being, contributing to SDG 3. Sustainable investments are made in companies with the majority of activities (as measured by turnover, enterprise value, or for pre-revenue companies R&D spend, or similar metrics) related, but not limited to the sale of innovative medicines, discovery of new mechanisms of action offering potential cures or better management of diseases that were difficult to treat before, medical device companies developing innovative technologies that improve patient outcomes, healthcare services and digital health companies that drive greater efficiency within healthcare systems, life science tools companies that enable innovation, as well as emerging-market drug and device manufacturers that help increase access and improve affordability of healthcare in developing geographies. Medical breakthroughs have the power and potential to improve people's life expectancy and quality of life. Therefore, the focus on medical progress, innovation, and improved access to modern medicine helps meet the objective of improved health and well-being.

To achieve the investment objective, the Sub-Fund's net assets are primarily invested in equities, equity-like transferable securities, participation certificates etc. issued by innovative healthcare companies developing differentiated drugs, services, life science tools and devices in therapeutic areas with large unmet medical needs. Investments are made across all market caps and geographies, including the emerging markets, with significant exposure to mid- and small-cap companies.

The Sub-Fund follows an ESG Integration approach and will include a sustainable investment proportion by applying an SDG 3 alignment approach. Additionally, the Sub-Fund follows an Active

Ownership strategy. It conducts voting and engagement activities, which are among others, related to ESG factors.

The Investment Manager measures the alignment of an investee company with the Sub-Fund's E/S Characteristics promoted by evaluating the degree to which the relevant company's activities, as measured by turnover (or for pre-revenue companies R&D spend), contribute to SDG 3. Further, the issuer's broader ESG profile is assessed by the Investment Manager who relies on ESG ratings from the third-party data provider Sustainalytics. Where the Investment Manager has concerns about an issuer's ESG profile, the Investment Manager may engage with the company to obtain further information or to encourage appropriate action to redress these concerns.

The Investment Manager monitors the Sub-Fund's investee companies' alignment with the promoted characteristics and with its broader ESG framework on at least a quarterly basis.

The Investment Manager notes the inherent limitations in evaluating companies' ESG standards and alignment with SDG 3, due to challenges in the availability, quality, comparability, and timeliness of both financial and sustainability data.

The Sub-Fund does not have a reference benchmark to measure the performance of its characteristics.

## **About Sectoral Asset Management**

---

Sectoral Asset Management was founded in 2000 and is exclusively focused on managing global healthcare portfolios. Sectoral continuously aims to achieve superior returns for our investors by concentrating on primary research.

Our investment philosophy is grounded in the belief that financial performance can go hand in hand with driving lasting

benefits for society through improved health and well-being.

Sectoral has one of the longest track records in managing biotech equities and provides investment management services to healthcare and biotech funds offered by partners in Europe and Asia. The firm is employee owned and registered with the SEC, AMF and the SFC.